On CNBC's "Mad Money Lightning Round," Jim Cramer said Affirm Holdings Inc (AFRM) is a buy. "It's at $72, it's going to $100," he noted. Affirm will announce its fourth quarter fiscal year results after the closing bell on Aug. 28. When asked about Eli Lilly and Co (LLY), he said, "Down here, I begin to think that we are too negative on it. But I am very upset with Lilly and the way they handled this, and I think they should come back on and talk to me." As per the recent news, Eli Lilly, on Aug. 7, released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist. Cramer said, "I don't want to be connected with Brazil," when asked about Banco Bradesco SA (BBD). "It's had a big run. If you want an overseas bank, I think you should be in Santander." On May 28, Citigroup analyst Rafael Frade upgraded Bank Bradesco from Neutral to Buy. Cramer said, "I think longer term, ServiceNow (NOW) has really good AI, and it would not be a stock that I would want to bet against. So, ServiceNow longer term I think is fine. Shorter term I think it's going to be under pressure." ServiceNow, on July 23, reported second-quarter revenue of approximately $3.22 billion, beating the consensus estimate of $3.12 billion, according to Benzinga Pro. The company reported second-quarter adjusted earnings of $4.09 per share, beating analyst estimates of $3.57 per share. Price Action: Eli Lilly shares gained 1.5% to settle at $635.22 on Monday. Affirm shares rose 0.9% to settle at $72.97. Banco Bradesco shares closed at $2.90 on Monday. ServiceNow shares declined 1.9% to close at $856.37.

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's 'Mad Money Lightning Round,' Jim Cramer expresses a bullish outlook on Affirm Holdings Inc, predicting its stock price will reach $100 from its current level of $72.97. He also criticizes Eli Lilly and Co for its handling of the Phase 3 ATTAIN-1 trial results for orforglipron, an investigational GLP-1 receptor agonist, and urges the company to engage with him. Cramer dismisses Banco Bradesco SA as a potential overseas banking investment, recommending Santander instead. He praises ServiceNow's long-term AI capabilities, noting it is not a stock he would bet against, despite short-term price pressure. ServiceNow reported strong second-quarter revenue and earnings, exceeding analyst expectations. Stock prices for Affirm, Eli Lilly, Banco Bradesco, and ServiceNow are reported for the trading day ending on August 7, 2025.